Nascent Biotech (NBIO)

Overall impact
B (76)

Commentary

Nascent Biotech is a strong overall performer. With a 'B' rating of 76.1 for overall impact (90th percentile compared to all companies), Nascent Biotech ranks 120th out of 585 industry peers, behind Biogen, Amgen, Regeneron Pharmaceuticals and 116 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 462 others. On top material causes for Nascent Biotech's industry (Pharmaceuticals & Biotech), Nascent Biotech performs well in Child and Maternal Health (88.9 score), Disease Eradication (96.4), Access to Affordable Healthcare (95.9) and 5 other causes where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (36.3 score) and Disaster Readiness and Effective Aid (35.8).
Impact
Cause NBIO
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2014
Employees
1
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Fl, United States
Share classes
NBIO
Description
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company that develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is also developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.
Material causes
Ethos considers the following causes material for Nascent Biotech, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.